CanniMed Therapeutics (CMED.TO)

This has a good advantage in that they have already expanded, and have 7000 kg per year capacity of dried bud, whereas others are planning that. They can go from sales level of about a tenth of that, to a higher level very quickly. Pesticides and contaminants are a big issue, and this company has pharmaceutical grade manufacturing at their Saskatoon facility of 97,000 ft.². They also have a facility in Michigan. They’ve been doing this for a long time. He likes medical more than recreational. He would wait for a lower price.

This has been focused strictly on the medical market, and not the recreational market. The stock is below where it was issued last December, probably because they have not talked about a recreational strategy.